Why Genetic Technologies (GENE) Stock Is Spiking Today

NEW YORK (TheStreet) -- Genetic Technologies (GENE) shares are up 13.2% to $1.16 on Monday after the company announced that the number of BREVAGen breast cancer risk test samples it received this quarter was up 37% over the previous quarter.

The company more than doubled the number of samples it received -- 3,935 compared to 1,547 -- for the fiscal year ending June 30 than it did the previous fiscal year.

The test is a cheek swab was introduced in the U.S. in 2012 that upon completion is sent to Genetic Technologies for analysis.

Must ReadWarren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping